BRCA1 and neoplasm: The lack of functional BRCA (mainly, BRCA1) can lead to increased sensitivity of the tumor cells to molecular damage, demonstrating that BRCA mutations represent a predictive marker of response to DNA-damaging chemotherapies [39-41].